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We have evaluated the inﬂuence of age and immunization routes for induction of HIV-1- and M. tuberculosis-speciﬁc immune
responsesafterneonatal(7daysold)andadult(7weeksold)BALB/cmiceimmunizationwithBCG.HIVA222 primeandMVA.HIVA
boost. The speciﬁc HIV-1 cellular immune responses were analyzed in spleen cells. The body weight of the newborn mice was
weeklyrecorded. Thefrequencies ofHIV-speciﬁc CD8+ TcellsproducingIFN-γ werehigherinadultmicevaccinatedintradermally
and lower in adult and newborn mice vaccinated subcutaneously. In all cases the IFN-γ production was signiﬁcantly higher when
mice were primed with BCG.HIVA222 compared with BCGwt. When the HIV-speciﬁc CTL activity wasassessed, the frequencies of
speciﬁc killing were higher in newborn mice than in adults. The prime-boost vaccination regimen which includes BCG.HIVA222
and MVA.HIVA was safe when inoculated to newborn mice. The administration of BCG.HIVA222 to newborn mice is safe and
immunogenic and increased the HIV-speciﬁc responses induced by MVA.HIVA vaccine. It might be a good model for infant HIV
and Tuberculosis bivalent vaccine.
1.Introduction
According to the last AIDS epidemic update released by
UNAIDS on November 2010, an estimated 33.3 million
people are currently living with HIV, and 2.6 million
individuals became newly infected with the virus in 2009.
Over the past year, the global AIDS epidemic killed 1.8
million people, and the number of children orphaned by
AIDS was 16.6 million. It is estimated that 97% of these new
infectionsoccurinlow-andmiddle-incomecountries,where
ensuring universal access to antiretrovirals still represents an
enormous challenge [1, 2]. In some sub-Saharan countries,
the HIV prevalence among pregnant women can be over
30%. Approximately half of mother-to-child transmissions
(MTCTs) are due to prolonged breastfeeding. Although
around 35% of HIV-positive pregnant women are receiving
antiretroviral therapy [1], reducing signiﬁcantly mother-to-
child transmission of HIV at delivery, the drugs have a high
cost, have to be administrated after delivery, and maintained
during the breastfeeding period, and the eﬃcacy could be
reduced due to emergence of resistant mutants.
Neonatal immunity is immature compared to the adult
immune system. CD8+ T-cell responses that may be critical
to control intracellular pathogens including HIV and Mtb
are inherently limited in human neonates. However, human
and murine neonates generate functional Th1-type immune
responses after infections with viruses or immunization with
live-attenuated immunogens that deliver antigens into the
cytoplasm of antigen presenting cells (APCs) [3]. Neonatal
immunization could be the best approach to prevent infec-
tion or reduce the severity of HIV-related disease in these
infants. Only two candidates vaccines designed to protect2 Clinical and Developmental Immunology
against breast milk HIV transmission have been studied in
human infants. Therefore, there is an urgent need for a
neonatal immunogen that generates HIV-speciﬁc immunity
more rapidly. Recombinant BCG has been developed as a
candidate neonatal vaccine vector against pertussis, measles,
respiratory syncytial virus (RSV), and breast milk HIV
transmission [3, 4].
BCG as a vaccine vector has a number of attractive
features [5, 6]. BCGhas a provenrecord ofsafety as a vaccine
against tuberculosis from its use in over two billion indi-
viduals including neonates [7]. BCG infects and colonizes
macrophages and dendritic cells, where it can survive and
replicate for a long period of time. Through its persistence
and potent adjuvantation by its cell wall components, it can
inducelong-lasting humoral and cellularimmune responses.
BCG can be given at or any time after birth and is not
aﬀected by maternal antibodies. Manufacturing of BCG-
based vaccines is cheap and easy to purify. Finally, BCG is
o n eo ft h em o s th e a t - s t a b l ev a c c i n e si nc u r r e n tu s e[ 8].
There is strong evidencesupporting a role ofcytotoxicT-
lymphocytes (CTLs) in the containment of HIV replication,
and several vaccine approaches are being pursued to elicit
anti-HIV CTL responses [9–12]. One promising approach
is that provided by Mycobacterium bovis Bacillus Calmette-
Gu´ erin (BCG) as a live recombinant bacterial vaccine vector.
WehavebeendevelopingarecombinantBCG-basedHIV
v a c c i n et oi n d u c ep r o t e c t i v ec e l l - m e d i a t e dr e s p o n s e s .O u r
starting platform was based on a heterologous BCG prime
and modiﬁed vaccinia virus Ankara (MVA) boost regimen
delivering a common immunogen called HIVA, which is
derived from consensus HIV-1 clade A Gag protein, that
is, an immunogen derived from an HIV-1 strain prevalent
in Central and Eastern Africa, and a string of CD8+ T-cell
epitopes [13]. The recombinant Mycobacterium bovis Bacil-
lus Calmette-Gu´ erin (BCG) expressing HIVA immunogen
has shown to be stable and to induce durable, high-quality
HIV-1-speciﬁc CD4+ and CD8+ T-cell responses in BALB/c
mice. Furthermore, when the recombinant BCG vaccine
was used in a priming-boosting regimen with heterologous
components, the HIV-1-speciﬁc responses provided protec-
tion against surrogate virus challenge, and the recombinant
BCG vaccine alone protected against aerosol challenge with
M. tuberculosis [14]. The BCG.HIVA222 vaccine candidate
was vectored by a lysine auxotroph of BCG Pasteur strain
that carried an E. coli-mycobacterial shuttle plasmid with
a lysine A complementing gene and a weak promoter to
regulate HIVA gene expression. This construction increases
the plasmid stability in vivo and prevents heterologous gene
expression disruption by genetic rearrangement [14, 15].
Infection with Mycobacterium tuberculosis kills about 2
million people each year [16]. Mycobacterium bovis Bacillus
Calmette-Gu´ erin (BCG) is the only licensed vaccine and
protects signiﬁcantly against childhood and miliary tuber-
culosis [17]. Globally, 80 percent of children are vaccinated
with BCG, the majority of them at birth [18]. Thus, the
development of a combined vaccine, which would protect
neonates against tuberculosis and MTCT of HIV-1 through
breastfeeding, is a logical eﬀort in the ﬁght against these two
majorglobalkillers.Immunityagainsttuberculosisfollowing
neonatal BCG vaccination lasts 10 to 15 years and thus fails
to protect adults from pulmonary disease [19, 20]. However,
a 10-year immunity to HIV-1 would be an excellent start.
We believe that the best hope to protect newborn
children against MTCT of HIV-1 in developing countries
is the development of a safe, eﬀective, and aﬀordable
prophylactic vaccine, which would both reduce the adult
burden of infection and protect neonates against vertical
HIV-1 transmission. In the present study, we have evaluated
the inﬂuence of age and immunizations routes for induction
of HIV-1 and M. tuberculosis-speciﬁc immune responses
after BALB/c mice immunization with BCG.HIVA222 prime
and MVA.HIVA boost. The administration of BCG.HIVA222
to newborn mice is safe and immunogenic and increased
the HIV-speciﬁc responses induced by MVA.HIVA vaccine.
It might be a good model for infant HIV and Tuberculosis
bivalent vaccine.
2.Materialsand Methods
2.1. E. coli/mycobacterial Vector Expressing HIVA Antigen.
The construction of E. coli/mycobacterial vector expressing
HIVA antigen [13] was previously described [14]. Brieﬂy, the
coding sequence of the HIVA immunogen (consensus HIV-1
cladeAGagproteinandastring ofCD8+ T-cellepitopes)was
fused to the M. tuberculosis nucleotides coding for the 19-
kDa lipoprotein signal sequence in a PCR, and the chimeric
genewasclonedintothepJH222E.coli-mycobacterialshuttle
plasmid (kindly provided by W. R. Jacobs Jr. and B. R.
Bloom) as a HindIII-HindIII fragment under the control of
the M. tuberculosis α-antigen promoter by using standard
recombinant-DNA techniques.
2.2. Electroporation of Mycobacteria and Culture. Al y s i n e
auxotrophic strain of BCG was kindly provided by W.
R. Jacobs Jr., B. R. Bloom, and T. Hsu. Mycobacterial
cultures were grown in Middlebrook 7H9 broth medium
or on Middlebrook agar 7H10 medium supplemented with
Middlebrook ADC(albumin,dextrose, catalase)Enrichment
(Difco) and containing 0.05% Tween 80 and 25μgo f
kanamycin/mL. The L-lysine monohydrochloride (Sigma)
was dissolved in distilled water and used at a concentration
of 40μg/mL. The plasmid pJH222HIVA was transformed
into BCG lysine auxotrophic strains by electroporation.
Cultures were grown to an OD of 0.9 (600nm), pelleted
at 3,000rpm, washed twice by resuspension and centrifu-
gation (3,000rpm) in 10% glycerol at 4◦C, and ﬁnally
resuspended in 1/20th of the original culture volume of
cold 10% glycerol. Then 100μL of the cold BCG suspension
was mixed with plasmid DNA (50–500ng) in a prechilled
0.2cm electroporation cuvette and transformed using the
BioRad Gene Pulser electroporator at 2.5kV, 25mF, and
1,000Ω. After electroporation1mL of7H9medium (Difco),
supplemented with albumin-dextrose-catalase (ADC, Difco)
and containing 0.05% Tween 80 (SIGMA), was added
and incubated at 37◦C for 12 hours before plating onto
Middlebrookagar7H10medium(Difco)supplementedwith
ADC (Difco) and containing 0.05% Tween 80 (SIGMA) and
25μg/mL of kanamycin.Clinical and Developmental Immunology 3
2.3. Western Blot Analysis. BCG transformants were grown
to mid-logarithmic phase in liquid 7H9 (Difco) medium
supplemented with albumin-dextrose-catalase (ADC, Difco)
and containing 0.05% Tween 80 and kanamycin (25μg/mL).
rBCG cultures were centrifuged at 3,000rpm for 10 minutes
at4◦C.PelletswerewashedtwiceinPBSplus0.02%Tween80
and resuspended in 1mL of extraction buﬀer (50mM Tris-
HClpH7.5,5mMEDTA,0.6%sodiumdodecylsulfate),and
5μL of 100x protease inhibitor cocktail (1mg/mL aprotinin,
1mg/mLE-64, 1mg/mL leupeptin, 1mg/mL pepstatin A,
50mg/mL pefabloc SC, and 10mL DMSO) was added.
Cells were sonicated for 4 minutes on ice with a Branson
Soniﬁer at output control seven, duty cycle 50%. Extracts
were centrifuged at 13,000rpm for 10 minutes at 4◦C, and
supernatants were collected. Proteins were separated on
15% SDS-polyacrylamide gel. HIVA protein was detected
using anti-Pk antibodies with an ECL kit (Amersham
International).
2.4. Mice. Six BALB/c female mice per group, 7 weeks old
(adult) and 7 days old (newborn), were used. The animal
experiment was approved by the local ethical committee for
animal experiments from the University of Barcelona and
strictly conformed to Catalan Animal Welfare legislation.
2.5. Immunization and Isolation of Splenocytes. Adult
mice were immunized intradermally with 2 × 106 CFU
of BCG.HIVA222 or subcutaneously with 106 CFU
of BCG.HIVA222. Newborn mice were immunized
subcutaneously with 2 × 106 CFU of BCG.HIVA222.
Adult and newborn mice were boosted 14 weeks after BCG
inoculation with 106 PFU of MVA.HIVA intramuscularly,
and 3 weeks later the animals were sacriﬁced. The animals
were sacriﬁced by cervical dislocation. The newborn mice
were weighted weekly for the safety testing of the vaccine.
On the day of sacriﬁce, spleens were removed and pressed
individually through a cell strainer (Falcon) with a 5mL
syringe rubber plunger. Following the removal of red blood
cells with red blood cell lysing buﬀer (Sigma), splenocytes
were washed and resuspended in lymphocyte medium
(RPMI 1640 supplemented with 10% fetal calf serum (FCS)
and penicillin-streptomycin, 20mM HEPES, and 15mM
β-mercaptoethanol) at a concentration of 2 × 107 cells/mL.
2.6. Peptides. For assessing the immunogenicity of HIVA
in the BALB/c mice, the following peptides were used:
H-2Dd-restricted epitope P18-I10 (RGPGRAFVTI), herein
designated epitope H. The PPD (Puriﬁed Protein Derivative,
Statens Serum Institute, Copenhagen) was used to assess the
immunogenicity induced by Mycobacterium bovis BCG.
2.7. In Vitro Killing Assay. P815 cells (mouse lymphoblast-
like mastocytoma cell line) were used as target cells.
They were incubated (pulsed) without or with 2μgo f
H peptide/mL in R10 at 37◦Ci n5 %C O 2 for 90min
and washed three times. Target cells not pulsed with
peptidewere labeledwith5-(and-6)-(((4-chloromethyl)ben-
zoyl)amino)tetramethyl rhodamine (CMTMR; Molecular
Probes) only, while peptide-pulsed target cells were labeled
with carboxyﬂuorescein diacetate succinimidyl ester (CFSE,
Molecular probes). Brieﬂy, H peptide-pulsed P815 cells
resuspended in phosphate-buﬀered saline (PBS) at 2 ×
107 cells/mL were incubated with 80nM CFSE in the dark
at room temperature for 10min, followed by the quenching
of the reaction with an equal volume of FCS and three
washing stepswithR10.Hpeptide-pulsedcells(andsimilarly
control nonpulsed cells) were thenresuspended in R10at2×
107 cells/mL and incubated with 10μM CMTMR at 37◦Cf o r
15min and in fresh R10 only for a further 15min. Cells were
washed 3 times as previously described. Finally, pulsed and
non pulsed P815 cells were mixed at 1:1 ratio. Splenocytes
obtained from vaccinated mice and expanded for 5 days in
lymphocyte medium containing 2μg/mL of H peptide were
harvested and counted. In a 96-well round bottom plate,
200μL of a suspension containing 106 expanded splenocytes
were placed in duplicate wells, and two 2-fold dilutions
in R10 were performed. On top, 100μL of a suspension
contained the mixture of pulsed and unpulsed P815 cells,
104 of each (at 100:1, 50:1, and 25:1 eﬀector:target cells
ratio). After a minimum of 5h of reaction, the cells were
ﬁxed and analyzed by ﬂow cytometry. Cytotoxicity was
calculated using the following formula: adjusted percentage
of surviving cells = 100 × (percentage of surviving peptide-
pulsed cells/mean percentage of surviving unpulsed cells).
Next,thepercentageofspeciﬁclysiswascalculatedasfollows:
percentage of speciﬁc lysis = 100 − adjusted percentage of
surviving cells [21]. The speciﬁc CTL activity was assessed
between the BCGwt or BCG.HIVA222 primed mice.
2.8. Intracellular Cytokine Staining. Two million splenocytes
were added to each well of a 96-well round-bottomed
plate (Falcon) and pulsed with 2 (CD8 epitopes) to
5μg/mL(CD4epitopes)peptidesor5μg/mLPPD tuberculin
(Statens Serum Institut, Copenhagen, Denmark) together
with antibodies against lysosomal-associated membrane
proteins anti-CD107a-FITC/anti-CD107b-FITC (BD Bio-
sciences) [22]a n dk e p ta t3 7 ◦C, 5% CO2 for 90 minutes,
followed by the addition of GolgiStop (BD Biosciences) con-
t a i n i n gm o n e n s i n .A f t e raf u r t h e r5 - h o u ri n c u b a t i o n ,r e a c -
tion was terminated, and the cells were washed with FACS
wash buﬀer (PBS, 2% FCS, 0.01% Azide) and blocked with
anti-CD16/32 (BD Biosciences) at 4◦Cf o r3 0m i n u t e s .A l l
subsequent antibody stains were performed using the same
conditions. Cells were then washed and stained with anti-
CD8-PerCP or anti-CD4-PerCP (BD Biosciences), washed
again, and permeabilized using the Cytoﬁx/Cytoperm kit
(BD Biosciences). Perm/Wash buﬀer (BD Biosciences) was
used to wash cells before staining with anti-IL-2-FITC, anti-
TNF-α-PE, and anti-IFN-γ-APC (BD Biosciences). Cells
wereﬁxedwithCellFIX(BD)andstoredat4◦Cuntilanalysis.
2.9. Ex Vivo IFN-γ ELISPOT Assay. The ELISPOT assay was
performed using the Mabtech IFN-γ ELISPOT kit according
to the manufacturer’s instructions. The ELISPOT plates
(Millipore ELISPOT plates) were coated with puriﬁed anti-
mouse IFN-γ capture monoclonal antibody diluted in PBS
to a ﬁnal concentration of 5ug/mL at 4◦C overnight. The4 Clinical and Developmental Immunology
plates were washed once in R10 and blocked for 2h with
R10. A total of 5 × 105 fresh splenocytes were added to
each well, stimulated with 2μg/mL of the H peptide or
5μg/mL of PPD for 16h at 37◦C, 5% CO2,a n dl y s e db y
incubating twice with deionized water for 5 minutes. Wells
were then washed 3x with PBS 0.05% Tween 20, incubated
f o r2hw i t hab i o t i n y l a t e da n t i - I F N - γ mAb diluted in PBS
2% FCS to a ﬁnal concentration of 2ug/mL, washed 3x in
PBS 0.005 Tween 20, and incubated with the Streptavidin-
Alkaline Phosphatase-conjugate in PBS 2% FCS. Wells were
washed 4x with PBS 0.005 Tween 20 and 2x with PBS before
incubating with substrate solution (Alkaline Phosphatase
Substrate, BioRad). After 5–10 minutes, the plates were
washed with tapwater, dried,and theresultingspotscounted
using an ELISPOT reader (AIC).
2.10. Fluorescence-Activated Cell Sorter Analysis. All chro-
mogen-labeled cells were analyzed in a Becton Dickinson
FACScalibur, using the CellQuest software for acquisition
(BD Biosciences) and the Flow-Jo software (Tri-Star) for
analysis.
2.11. Statistical Analysis. Data are the means ± SEM (stan-
dard error or the mean) for six mice per group. Statistical
signiﬁcance was determined by ANOVA (∗ = P<. 05;
∗∗ = P<. 01; ∗∗∗ = P<. 001).
3.Results
3.1. Recombinant Mycobacterium bovis BCG Expressing HIV-
1 Clade A Immunogen. HIVA immunogen consists of con-
sensus HIV-1 clade A gag p24/p17 domains coupled with
as t r i n go fC D 8 + T-cell epitopes and monoclonal antibody
(mAb) tag Pk [13]. The HIVA gene was synthesized utilizing
humanized GC-rich codons, which are similar to those used
bymycobacteria [23–25].The HIVAopen-reading frame was
fused at its 5  end to nucleotides coding for the 19-kDa
lipoprotein signal sequence, which facilitates expression of
foreign proteins in the mycobacterial membrane and was
shown to increase the foreign protein immunogenicity [26].
To facilitate the preclinical development of candidate vac-
cines, the HIVA immunogen contains an immunodominant
H-2Dd-restricted epitope P18-I10 [27], here designated also
as H epitope. In addition, it also contains at least three
other subdominant H-2Dd epitopes recognized by CD8+ T
cells including epitope P and three CD4+ T-helper epitopes
(unpublished). The chimeric 19-kDa signal sequence-HIVA
gene was expressed from Escherichia coli/mycobacterium
shuttle plasmid pJH222 under the control of the M. tuber-
culosis α-antigen promoter (Figure 1(a)). pJH222 is a low-
copy replicative episomal vector and contains mycobacterial
origin of replication (oriM). It contains also an expres-
sion cassette encoding kanamycin resistance (aph), E. coli
origin of replication (oriE) ,a n daw i l d - t y p el y s i n eA -
complementing gene for the vector maintenance (lysA5)
in the BCG auxotroph. Recombinant pJH222.HIVA was
transformed into lysine auxotroph of M. bovis BCG host
strain Pasteur
￿lysA5::res [28]. Expression of the full-size
HIVA aph oriE oriM/int lysA
19-kDa lipoprotein signal
mAb tag Pk
Pα-Ag PHSP60
H-2d class II epitopes
H-2d class I epitopes
(a)
pJH222HIVA
BCG
wt
123
207
116
96
55
37
30
HIVA
(kDa)
anti-PK
BCG.HIVA222
(b)
Figure 1: Expression of the HIVA immunogenfrom BCG.HIVA222.
(a) A synthetic GC-rich HIVA gene consisting of consensus was
fused to the 19-kDA lipoprotein signal sequence and inserted into
episomal pJH222 E. coli-mycobacterium shuttle plasmid. This con-
tains a kanamycin resistance gene (aph) and complementing lysA
genes and E. coli origin of replication (oriE). In addition, pJH222
contains mycobacterial origin of replication (oriM). BALB/c mice
T-cell and mAb Pk epitopes used in this paper are depicted. Pα-Ag,
M. tuberculosis α-antigen promoter; PHSP60, heat shock protein
60 gene promoter. (b) Western blotting of lysates of BCG.HIVA222
containing the pJH222HIVA (lanes 1 and 2) and BCG wild type
(lane 3; negative control) is shown. HIVA was detected using the
anti-Pk mAb followed by HRP-protein A and ECL.
chimeric19-kDasignalsequence-HIVAproteinofMr 65kDa
was conﬁrmed on a Western blot of whole transformed
mycobacterial cell lysates using anti-Pk mAb (Figure 1(b)).
3.2. BCG.HIVA222 Prime and MVA.HIVA Boost Elicited
Func-tional HIV-1-Speciﬁc CD8+ T-Cell Responses. We have
demonstrated in previous studies with BALB/c mice that
BCG.HIVA222 can both prime novel and boost preexisting
MVA.HIVA-elicited HIV-1-speciﬁc CD4+ and CD8+ cellular
immune responses of high quality upon antigenic reexpo-
sure [14]. In this study we have evaluated the eﬀect of
BCG.HIVA222 priming using diﬀerent routes and mice age
(adult and newborn) on the induction of HIV-1-speciﬁc
T-cell responses after BALB/c mice immunization with
BCG.HIVA222 prime and MVA.HIVA boost. The immuno-
genicity readout was focused on the P18I10 epitope, an
immunodominant CTL epitope derived from HIV-1 Env
and H-2Dd restricted [27], here mentioned as H, which was
fused to HIVA immunogen to evaluate the immunogenicity
in mice (Figure 1(a)). On day 0, mice were immunized
with rBCG with the episomal plasmid or BCG wild type,Clinical and Developmental Immunology 5
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Figure 2: Eﬀect of BCG.HIVA222 priming on the induction ofHIV-
1-speciﬁc CD8+ T cells. (a) Mice were immunized with 2 × 106 cfu
(adult mice I.D. or neonates S.C.) or 106 cfu (adult mice S.C.) of
BCG.HIVA222 andsubsequently boosted 14 weeks later with 106 pfu
of MVA.HIVA by i.m. route. (b and c) Analysis of IFN-γ and TNF-
α vaccine-elicited CD8+ T cells as generated for each vaccination
group by using the P18I10 epitope. The frequencies of CD8+ T cells
producing IFN-γ orTNF-α are shown.Data are presented as means
± standard deviation (SD; n = 6). (d) Elicitation of speciﬁc T-
cell responses was assessed in an IFN-γ ELISPOT assay using the
immunodominant P18I10 CD8+ T-cell epitope peptide. The mean
(± SEM) sfu per 106 splenocytes for each group of mice (n = 6p e r
group) is shown. BCG.HIVA222 primed mice: striped bars. BCGwt
primed mice: white solid bars. ∗ = P<. 05; ∗∗ = P<. 01,
∗∗∗ = P<. 001.
and on day 102 the animals received a booster dose with
MVA.HIVA. On day 151, the mice were sacriﬁced, and the
functional speciﬁc T cells in response of peptide stimulation
were measured by intracellular cytokine staining (ICS)
and ELISPOT assays (Figure 2(a)). We have observed in
adult and newborn mice that BCG.HIVA222 prime and
MVA.HIVA boost induced higher frequencies of H-speciﬁc
CD8+ splenocytes producing IFN-γ and TNF-α compared
with the BCG wild-type priming and MVA.HIVA boost
in two analyses performed (Figures 2(b), 2(c),a n d2(d)).
Overall, the proportions of HIV-1-speciﬁc T cells producing
IFN-γ and TNF-α were higher in adult mice compared
with newborn mice. When adult mice were vaccinated
intradermally, the BCGwt priming elicited 1.45% of CD8+
T cells producing IFN-γ, in comparison with 2.18% when
the priming was performed with BCG.HIVA222.W eh a v e
detected the same pattern but lower magnitude when adult
mice were immunized subcutaneously, 0,69% and 1,02%,
respectively. When the newborn mice were primed with
BCGwt or BCG.HIVA222 subcutaneously, the results were
0.37% and 0.59%, respectively (P<. 05). The frequency of
speciﬁcCD8+ splenocytesproducingIF-γ wastwofoldhigher
(P<. 01) when adult mice were primed with BCG.HIVA222
intradermally compared with subcutaneously and nearly 4-
fold higher when compared with newborn mice (P<. 001)
(Figure 2(b)). The proportion of speciﬁc CD8+ splenocytes
producing TNF-α was higher when mice were inoculated
with BCG.HIVA222 (1.66% for adult and I.D. route and
1.50% for Newborn and S.C. route) in comparison with
those inoculated with BCGwt (1.05% and 0.75%, resp.). In
newborn mice, this diﬀerence was signiﬁcant (P<. 001). In
contrast, the proportion was slightly higher in adult mice
using BCGwt priming subcutaneously (1.42%) compared
with BCG.HIVA222 priming (1.29%) (Figure 2(c)).
The capacity of splenocytes from vaccinated mice to
secrete IFN-γ was tested also by ELISPOT assays. The
splenocytes secreted IFN-γ after overnight stimulation with
the dominant CD8+ T-cell P18I10 epitope peptide. Rep-
resentative results obtained with splenocytes from mice
primed with BCG.HIVA222 or BCG wild type and boost
with MVA.HIVA are shown in Figure 2(d). In adult and
newborn mice the frequency of speciﬁc cells secreting IFN-
γ was higher in mice primed with BCG.HIVA222 (455 and
367 spot forming units, (sfu)/106 splenocytes for adult and
newborn mice, resp.) compared with BCG wild-type (329
and 303 sfu/106 splenocytes for adult and newborn mice,
resp.). Among adult mice, the diﬀerence was signiﬁcant (P<
.05).
3.3. Priming BCG.HIVA222 Route and Age Aﬀects the Level
and Quality of CD8+ T-Cell Responses to an Immunodom-
inant Epitope. We have evaluated the inﬂuence of route
inoculation and mice age on the level and quality of CD8+
T-cell responses induced after mice immunization with
BCG.HIVA222 p r i m ea n dM V A . H I V Ab o o s t .T h ei m m u n i z a -
tion schedule is described in Figure 2(a).T h eq u a l i t yo f
vaccine-elicited CD8+ T cells was monitored by bifunctional
analysis and in vitro killing assay for CTL activity. First,
the frequencies of bifunctional IFN-γ and TNF-α Tc e l l s6 Clinical and Developmental Immunology
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Figure 3: Induction of multifunctional HIV-1-speciﬁc CD8+ T cells by the BCG.HIVA222 prime and MVA.HIVA boost regimen. Analysis of
bifunctional vaccine-elicited CD8+ T cells using the P18I10 peptide stimulation. (a) Example of dot blots and region selection for analysis.
Region selected to analyze the splenocytes in the SSC-FSC dot-blot presentation (left), the CD8+ splenocytes selection (middle) and the
IFNγ and TNF-α staining of the CD8+ splenocytes (right). (b) This panel shows the frequencies of CD8+ T cells producing IFN-γ and/or
TNF-α. Data are presented as means ± SEM. (c) In vitro analysis of the CTL activity using peptide-pulsed target cells. BCG.HIVA222 primed
m i c e :s t r i p e db a r s .B C G w tp r i m e dm i c e :w h i t es o l i db a r s .∗ = P<. 05; ∗∗ = P<. 01, ∗∗∗ = P<. 001.Clinical and Developmental Immunology 7
speciﬁc for the H epitope were assessed. We found that the
magnitude of the bifunctional response was higher when the
I.D. route was used for BCG.HIVA222 priming in adult mice
compared with S.C. route in adult mice (P<. 01), and S.C.
route in newborn mice (P<. 01). In addition, when the
intradermal inoculation was performed, the proportion of
CD8+ splenocytes producing IFN-γ and TNF-α was more
than 2,5-fold higher in BCG.HIVA222 primed mice (1.77%)
compared with BCG wild-type primed mice (0.65%) (P<
.05). On the other hand, we observed the same trend
but in lower magnitude when adult mice were inoculated
subcutaneously with BCG.HIVA222 (0.58%), compared with
BCG wild type (0.40%). The magnitude of the bifunctional
r e s p o n s ew a sl o w e ri nn e w b o r nm i c et h a ni na d u l tm i c e .
Besides that, the frequency of speciﬁc CD8+ splenocytes
producing IFN-γ and TNF-α was higher in BCG.HIVA222
primed mice than in BCG wild-type primed mice (0.43 and
0.24%, resp., (P<. 05) (Figure 3(b)). Second, the cytotoxic
activity of the BCG.HIVA222-MVA.HIVA-elicited CD8+ T
cells was also assessed by in vitro killing assay. Splenocytes
were cultured and stimulated with the P18I10 peptide for
ﬁve days and evaluated as eﬀector cells. These eﬀector cells
were able to kill eﬃciently P815 target cells pulsed with
the P18I10 peptide. The frequency of speciﬁc killing was
h i g h e ri nn e w b o r nm i c et h a ni na d u l tm i c e .I nn e w b o r n
mice the proportion of speciﬁc CTL activity was higher after
BCG.HIVA222 priming(61%)comparedwithBCGwild-type
priming (27%), subcutaneously, P<. 001. In adult mice
the proportion of speciﬁc CTL activity was also higher after
BCG.HIVA222 priming (53%) compared with BCG wild-
type priming (34%) intradermally. In contrast, when adult
mice were vaccinated by S.C. route, the highest frequency
of speciﬁc killing was obtained when BCGwt priming was
used (24.4%), compared with BCG.HIVA222 priming (8.2%)
(Figure 3(c)). The frequency of speciﬁc killing was clearly
higher in adult mice primed with BCG.HIVA222 I.D. (P<
.001) and Newborn mice primed with BCG.HIVA222 S.C.
(P<. 001) in comparison with adult mice inoculated S.C.
3.4. BCG.HIVA222 Elicited PPD-Speciﬁc Responses in Mice.
TheBCG-speciﬁcimmune responses were assessed following
the vaccine regimen consisting of BCG.HIVA222 prime and
MVA.HIVAboostasdescribedinFigure 2(a).Thecapacityof
splenocytes from vaccinated mice to secrete IFN-γ was tested
by ELISPOT assays. The splenocytes secreted IFN-γ after
overnightstimulationwiththe PPDantigen. The frequencies
of speciﬁc cells secreting IFN-γ was higher in newborn mice
than in adult mice (261sfu and 147sfu/106 splenocytes,
resp., P<. 05). On the other hand, in newborn mice, the
proportion of speciﬁc cells secreting IFN-γ was identical
after BCG.HIVA222 priming compared with BCG wild-type
priming. (261 and 261sfu/million splenocytes). However, in
adult mice, the proportion of speciﬁc cells secreting IFN-γ
was lower after BCG.HIVA222 priming compared with BCG
wild-type priming (147 and 218sfu/million splenocytes,
resp.) (Figure 4).
3.5. BCG.HIVA222 Prime and MVA.HIVA Boost Regimen Was
Safe in Newborn Mice. Six newborn mice (7 days old) per
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Figure 4: PPD-speciﬁc T-cell responses elicited by BCG.HIVA222.
Immune responses to BCG were assessed in an ex vivo IFN-γ
ELISPOT assay using PPD as the antigen. The mean (± SEM) sfu
per 106 splenocytes for each group of mice (n = 6p e rg r o u p )i s
shown. BCG.HIVA222 primed mice: striped bars. BCGwt primed
mice: white solid bars. ∗ = P<. 05.
group were either immunized or left unimmunized with
2×106 cfuofBCGwildtypeorBCG.HIVA222 subcutaneously
route and subsequently given a booster dose of 106 pfu of
MVA.HIVA via intramuscular as described in Figure 2(a).A s
shown in Figure 5, the body weight was weekly monitored
and recorded. All vaccine combinations were analyzed,
to depict any possible adverse event due to vaccination
and monitored by body weight lost. For rigorous safety
assessment, the doseofBCGwt and BCG.HIVA222 inoculated
to newborn mice (2×106 cfu) was 10-fold higher, as advised
by the European Pharmacopoeia for the safety testing of
live vaccines, in comparison with the most usual inoculation
dose in adult mice [29]. Importantly, no diﬀerences were
observed between the vaccinated mice groups and the naive
mice group. On the other hand, the body weight proﬁle
was similar in all mice groups and similar to mice provider
companystandardbodyweightcurve.Furthermore,between
week 0 and week 14, the body weight monitored in all
vaccinated mice groups was found between the mean body
weight curve in na¨ ı v em i c ea n dt h eM V A . H I V Ag r o u p
(see Figure 5). Until week 14, the MVA.HIVA group can
be considered as a naive group, because it has not been
vaccinated yet. It is also important to mention that no
mice died during the trial. Only local adverse events were
detected in one mice showing slight redness and induration,
which disappeared after several weeks. When analyzed by
histopathology at necropsy, 17 weeks later, no severe lesion
was observed.
4.Discussion
Despite the progress made on prevention of mother-to-
child HIV-1 transmission, the development of a safe,
eﬀective, and aﬀordable vaccine against HIV and TB at
the earliest time after birth to prevent breast milk HIV
transmission and childhood tuberculosis is still a great
challenge. In the present study, we have evaluated the
inﬂuence of age and immunization routes for induction of
HIV-1 and M. tuberculosis-speciﬁc immune responses after8 Clinical and Developmental Immunology
BALB/c mice immunization with BCG.HIVA222 prime and
MVA.HIVA boost. We have observed (i) enhanced speciﬁc
T-cell induction responses in adult and newborn mice by
using BCG.HIVA222 priming compared with BCG wild-
type priming; (ii) higher frequencies and quality of the
speciﬁc T-cell responses in adult mice immunized with
BCG.HIVA222 intradermally compared with subcutaneously;
(iii) that the BCG-speciﬁc immune responses were higher
in newborn mice than adult mice; (iv) that among adult
micethe BCG-speciﬁc immune responses were lower in mice
primed with BCG.HIVA222 than BCG wild type; (v) that
the BCG.HIVA222 prime and MVA.HIVA boost regimen is
safe and immunogenic in newborn mice. Here, we have
used the BCG.HIVA222 strain previously constructed by our
group. This rBCG stably expresses the HIVA immunogen
from the episomal pJH222HIVA plasmid. The HIVA gene
was fused to the M. tuberculosis nucleotides coding for the
19-kDa lipoprotein signal sequence, and the HIVA gene
expression was under the control of Mycobacteria spp. α-
antigen promoter.
In murine and nonhuman primates studies, we and
others have shown that rBCG elicited antibody, and cell-
mediated responses against HIV-1 and simian immun-
odeﬁciency virus antigens [30–34]. In fact, only a small
proportion of these animal studies used rBCG strains
in heterologous prime-boost regimens. Ami et al. [35]
have demonstrated that macaques vaccinated with rBCG
expressing SIV gag and boosted with replication defective
poxvirus-SIV gag, elicited eﬀective protective immunity
against mucosal challenge with SHIV KS661c. There is
evident data showing that rBCG is a good priming vector
in heterologous prime-boost vaccination regimens with
attenuated virus or recombinant proteins to enhance speciﬁc
T-cell responses [14, 36–38]. In TB vaccine human trials,
McShane et al. [37] have demonstrated that vaccination
with MVA expressing Ag85 boosts preexisting antimycobac-
terial immune responses induced either by environmental
mycobacteria or BCG vaccination. Hovav et al. [39]h a v e
explored novel priming immunogens that might be used
in heterologous immunization regimens. They have shown
that priming with recombinant Mycobacterium smegmatis
expressing HIV-1 gp120 protein induced a cellular immune
response that is biased toward memory CD8+ T cells and
that can expand dramatically on reexposure to an HIV-
1 envelope antigen. Our laboratory, in collaboration with
Tom ´ aˇ sH a n k e ’ sl a b o r a t o r yh a v es h o w ni nB A L B / cm i c et h a t
theinclusionofBCG.HIVA222 in aheterologousprime-boost
regimen can both prime novel and boost preexisting HIV-1
speciﬁcT-cellimmuneresponseselicitedbyMVA.HIVA[14].
Many studies have compared the immune responses to
foreign antigens delivered by rBCG inoculated by diﬀerent
routes; however, comparisons are diﬃcult as doses, BCG
strains, mycobacterial expression vectors, in vivo plasmid
stability, promoters to regulate gene expression, levels of
heterologousproteinexpression, and antigen localization are
diﬀerent.Severalauthorshaveemphasized themucosalroute
of administration of rBCG. Lagranderie et al. [40]f o u n d
that intrarectal immunization of mice with rBCG-SIVmac251
induced higher intestinal IgA responses than oral or nasal
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Figure 5: Body weight curve after newborn mice vaccination with
BCG.HIVA222 (SC) and MVA.HIVA (IM). (a) Newborn mice were
either left immunized or immunized with 2 × 106 cfu of BCG
wild type or BCG.HIVA222 by subcutaneous route andsubsequently
given a booster dose of 106 pfu of MVA.HIVA as indicated in panel
A. (b and c) The body weight was weekly recorded, and the body
weight mean (± SEM) for each group of mice (n = 6p e rg r o u p )i s
shown. Two diﬀerent scales are shown so that the full evolution of
the body weight is seen (b), and the y-axes zoomed to the 15–25g
interval, so that the group diﬀerences are better seen (c).
immunization. Kawahara et al. [41] examined a combined
vaccination strategy in guinea pigs for enhancement of HIV-
1-speciﬁc immune responses. They found that combined
inoculation by rectal and intradermal routes eﬀectively
enhanced the levels of humoral and cellular immune
responses against HIV-1. Promkhatkaew et al. [42]h a v e
explored the inﬂuence of immunization routes after adult
BALB/cmice immunization with rBCG/HIV-1 gagE priming
and rDIs/HIV-1 gagE boosting. They found higher CTL
activity levels after two months subsequent to vaccination
when mice were primed with rBCG subcutaneously andClinical and Developmental Immunology 9
boostedwith rDIsintravenouslycompared withpriming and
boosting intradermally. However, after seven months subse-
quent to vaccination, they found similar CTL activity levels
when mice were primed with rBCG S.C. and boosted with
rDIsi.v. or intradermally. In the current study, BCG.HIVA222
prime- and MVA.HIVA boost-elicited HIV-1-speciﬁc CD8+
T-cells exhibited eﬀector functions such as production of
IFN-γ and TNF-α, and such HIV-1-speciﬁc T-cell responses
were higher in adult than in newborn mice. The inclusion
of BCG.HIVA222 in a heterologous prime-boost regimen
consistently enhanced and improved the frequency, quality,
and durability of the generated HIV-1-speciﬁc responses in
adult and newborn mice. This improvement was observed
by the detection of the highest bifunctional HIVA-speciﬁc
T-cell responses and higher speciﬁc cytolytic activity in
t h em i c et h a tr e c e i v e dB C G . H I V A 222 versus BCG wild
type. Among adult mice, the intradermal inoculation of
BCG.HIVA222 induced higher frequencies and quality of the
speciﬁc HIV-1 immune responses versus the subcutaneous
route. These results would be in accordance with the current
recommended route of inoculation of BCG in infants.
There are really few reports in the literature describing
the safety and immunogenicity of rBCG expressing HIV
antigens in neonatal miceand neonatal nonhuman primates.
Ranganathan et al. [43]h a v ee v a l u a t e dt h ei m m u n o g e n i c i t y
in neonatal mice of three diﬀerent recombinant attenuated
Mtb. strains expressing an HIV envelope. They showed
that single-dose immunization in neonatal mice with ΔlysA
ΔsecA2 Mtb strain expressing HIV Env rapidly generated
HIV-1- and Mtb-speciﬁc T-cell immune responses. In
the present study, we have shown in newborn mice that
BCG.HIVA222 primeand MVA.HIVA boostincreased thefre-
quencies of speciﬁc CD8+ T cells producing IFN-γ or TNF-
α. Such vaccine regimen also induced the highest proportion
of HIV-1-speciﬁc bifunctional cells and the speciﬁc cytolytic
activity. We have observed in newborn mice a lower level
of HIV-1-speciﬁc T-cell immune responses compared with
adult mice. Rosario et al. [44] have assessed the immuno-
genicity of the BCG.HIVA222 prime and MVA.HIVA boost
r e g i m e ni nn e w b o r nRhesus macaques.T h e ya l s oo b s e r v e d
that the HIV-1-speciﬁc responses induced in infants were
lower compared with adult animals. On the other hand, we
suggest that additional experiments should be performed
in newborn mice inoculating the rBCG expressing HIV
antigens by diﬀerent routes, because the route of neonatal
vaccinationmayconferdiﬀerentlevelsofimmuneactivation,
which may aﬀect the eﬃcacy of the vaccine.
Here, the vaccination with BCG wild-type and
BCG.HIVA222 strains inducedstrong BCG-speciﬁc responses
in adult and newborn mice. Studies in neonatal mice have
indicated that immune responses at birth are often biased
t o w a r d st h eT h 2t y p ea n dd e f e c t i v ei nt h eT h 1t y p e ,t h e
central defense mechanism against intracellular pathogens.
However,ithasbeendescribedthatBCGvaccination induces
a potent Th1-type immune response at birth in humans and
in mice [45–48].
Thechallengeforneonatalvaccinologyisthustodevelop,
and promote at a global level, vaccines that could be safely
administered soon after birth and would be eﬀective after
one or two early doses. According to our knowledge, no
reports have been published about safety of rBCG-based
HIV vaccine in neonatal mice. Rosario et al. [44]h a v e
demonstrated that BCGHIVA401 followed by two doses of
MVA.HIVA in Rhesus macaques was safe, not associated with
systemic reactions, and thelocaladverseeventsdetectedwere
considered to be consistent with a predicted response to
the BCG vaccine administration, similar to that observed in
human neonates. In the present study,we havedemonstrated
in neonatal mice (7 days old) that BCG.HIVA222 prime and
MVA.HIVA boost regimen was safe. We observed only in
one mouse a local reaction and induration, and no systemic
changes were observed after necropsy.
In conclusion, we tested the safety and immunogenic-
ity of two candidate HIV-1 vaccines, BCG.HIVA222 and
MVA.HIVA, in newborn mice using the prime-boost regi-
men. On the other hand we tested the inﬂuence of route
inoculation among adult mice. We found the vaccines safe
butlessimmunogenicforTcellsinnewborn micethan when
administered to adult animals. In adult mice we found that
t h ei n t r a d e r m a lr o u t eg a v eh i g h e rf r e q u e n c i e sa n dq u a l i t y
of the speciﬁc HIV-1 T-cell responses compared with the
subcutaneous route. Given the urgent and global need for
safe,eﬀective,andaﬀordableHIVandTBvaccinesforinfants
and the demonstrated capability to produce and administer
live mycobacterial vaccines on a large scale, BCG.HIVA222
prime and MVA.HIVA boost might be an attractive platform
for a human neonatal vaccine for prevention of tuberculosis
and mother-to-child breast milk transmission of HIV-1.
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